Belatacept

Pre-clinicalCompleted

0 watching 0 views this week💤 Quiet

Hype Score

Development Stage

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

End-Stage Renal Disease

Conditions

End-Stage Renal Disease

Trial Timeline

Mar 1, 2012 → Mar 1, 2018

NCT ID

NCT01496417

About Belatacept

Belatacept is a pre-clinical stage product being developed by Bristol Myers Squibb for End-Stage Renal Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT01496417. Target conditions include End-Stage Renal Disease.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (9)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00719225	Pre-clinical	Completed	—	—	Renal Transplantation
NCT02939365	Approved	Withdrawn	Feb 1, 2019	Dec 1, 2022	Transplantation
NCT03375138	Phase 1	Completed	Dec 4, 2017	Apr 2, 2019	Healthy Volunteers
NCT02327403	Phase 2	Completed	Oct 1, 2015	Oct 1, 2020	Proteinuria
NCT01953120	Approved	Completed	Oct 1, 2013	Apr 21, 2021	Renal Transplant Rejection
NCT01791491	Phase 2	Completed	May 9, 2013	Dec 6, 2016	Kidney Transplant
NCT01496417	Pre-clinical	Completed	Mar 1, 2012	Mar 1, 2018	End-Stage Renal Disease
NCT01033500	Pre-clinical	Withdrawn	Jul 1, 2010	Dec 1, 2012	Islets of Langerhans Transplantation
NCT00578448	Phase 2	Completed	Mar 1, 2008	Sep 1, 2012	Renal Transplantation

Competing Products

20 competing products in End-Stage Renal Disease

See all competitors

Product	Company	Stage	Hype Score
Conversion to Advagraf + conversion of non-immunosuppressant drugs to once daily + Conversion to once daily MPA	Astellas Pharma	Pre-clinical	23
donepezil HCl + donepezil HCl	Eisai	Approved	85
paricalcitol	AbbVie	Phase 3	77
daptomycin + daptomycin	Merck	Phase 1	33
Letermovir 480 mg [PREVYMIS]	Merck	Phase 1	33
MK-2060 + Placebo	Merck	Phase 2	52
Zepatier + Ribavirin + Sofosbuvir	Merck	Approved	85
MK-2060 + Placebo	Merck	Phase 1	33
daptomycin	Merck	Phase 1	33
MK-2060	Merck	Phase 1	33
MK-2060 + Placebo	Merck	Phase 1	33
Anti-Thymocyte Globulin vs Campath-1H vs Daclizumab	Roche	Approved	85
Avacopan	Amgen	Phase 1	32
Ranolazine	Gilead Sciences	Approved	84
Bosutinib + Bosutinib + Bosutinib + Bosutinib	Pfizer	Phase 1	32
CP-690,550	Pfizer	Phase 1	32
Rabbit Anti-thymocyte Immunoglobulin + Tacrolimus + Methylprednisolone + Mycophenolate mofetil + Mycophenolate Na + prednisone	Sanofi	Approved	84
Single-dose rabbit Anti-thymocyte Globulin induction + Divided-dose rabbit Anti-thymocyte Globulin induction	Sanofi	Phase 2	51
rabbit anti-thymocyte globulin - single dose + mycophenolate mofetil + rabbit anti-thymocyte globulin - 4 doses + sirolimus + tacrolimus	Sanofi	Approved	84
ISIS 416858 + Placebo	Bayer	Phase 2	49

Other Products from Bristol Myers Squibb

DeucravacitinibApproved

Aripiprazole + Olanzapine + HaloperidolApproved

Irbesartan + CiprofibrateApproved

Entecavir + Lamivudine Placebo + Lamivudine + Entecavir PlaceboApproved

deucravacitinibApproved